JP2025011102A5 - - Google Patents
Info
- Publication number
- JP2025011102A5 JP2025011102A5 JP2024163238A JP2024163238A JP2025011102A5 JP 2025011102 A5 JP2025011102 A5 JP 2025011102A5 JP 2024163238 A JP2024163238 A JP 2024163238A JP 2024163238 A JP2024163238 A JP 2024163238A JP 2025011102 A5 JP2025011102 A5 JP 2025011102A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- wisp1
- antibody
- liver disease
- antibody fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862747903P | 2018-10-19 | 2018-10-19 | |
| US62/747,903 | 2018-10-19 | ||
| JP2021521144A JP2022512735A (ja) | 2018-10-19 | 2019-10-18 | 肝疾患を治療するための組成物および方法 |
| PCT/US2019/056910 WO2020081920A1 (en) | 2018-10-19 | 2019-10-18 | Compositions and methods for treatment of liver disease |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021521144A Division JP2022512735A (ja) | 2018-10-19 | 2019-10-18 | 肝疾患を治療するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025011102A JP2025011102A (ja) | 2025-01-23 |
| JP2025011102A5 true JP2025011102A5 (https=) | 2025-08-19 |
Family
ID=70284106
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021521144A Withdrawn JP2022512735A (ja) | 2018-10-19 | 2019-10-18 | 肝疾患を治療するための組成物および方法 |
| JP2024163238A Pending JP2025011102A (ja) | 2018-10-19 | 2024-09-20 | 肝疾患を治療するための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021521144A Withdrawn JP2022512735A (ja) | 2018-10-19 | 2019-10-18 | 肝疾患を治療するための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20210388073A1 (https=) |
| EP (1) | EP3866852A4 (https=) |
| JP (2) | JP2022512735A (https=) |
| KR (1) | KR20210081366A (https=) |
| CN (2) | CN120305401A (https=) |
| AU (1) | AU2019361120A1 (https=) |
| CA (1) | CA3117098A1 (https=) |
| IL (1) | IL282251A (https=) |
| WO (1) | WO2020081920A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3154648A1 (en) | 2019-09-16 | 2021-03-25 | Opsidio, LLC | Anti-stem cell factor antibodies and methods of use thereof |
| US20220378843A1 (en) * | 2019-11-01 | 2022-12-01 | Figene, Llc | Fibroblast-based therapy for treatment of sclerosing cholangitis |
| CN117487010B (zh) * | 2022-08-02 | 2025-02-14 | 东莞市朋志生物科技有限公司 | 抗四碘甲状腺素抗体或其功能性片段、检测四碘甲状腺素的试剂和试剂盒 |
| AU2024232439A1 (en) * | 2023-03-03 | 2025-08-28 | Karydo Therapeutix, Inc. | Antibody or antigen-binding fragment of same |
| CN117045680B (zh) * | 2023-10-12 | 2023-12-08 | 北京国卫生物科技有限公司 | 促进肝脏再生的干细胞制剂及其制备方法 |
| WO2025179048A2 (en) * | 2024-02-20 | 2025-08-28 | Ecogenome Llc | Antibodies that bind dach1 and methods of use |
| CN119331100B (zh) * | 2024-10-16 | 2025-07-25 | 天津大学 | 特异性结合25-羟基维生素d的单克隆抗体及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2014770A3 (en) * | 1997-10-29 | 2009-02-18 | Genentech, Inc. | WNT-1 Iinduced secreted polypeptide WISP-2 |
| EP1177796B1 (en) * | 1999-04-27 | 2011-04-27 | Mitsubishi Tanabe Pharma Corporation | Medicament for prevention or therapeutic treatment of liver disease |
| JPWO2003014345A1 (ja) * | 2001-08-08 | 2004-11-25 | 味の素株式会社 | 肝星細胞活性化に関与する遺伝子パネル |
| CA2801066C (en) * | 2010-06-02 | 2021-02-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
| KR20160138580A (ko) * | 2014-04-15 | 2016-12-05 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Wisp1에 결합하는 항원 결합 단백질 |
| AU2015360502A1 (en) * | 2014-12-10 | 2017-06-29 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| US11015196B2 (en) * | 2016-05-20 | 2021-05-25 | The General Hospital Corporation | Using microRNAs to control activation status of hepatic stellate cells and to prevent fibrosis in progressive liver diseases |
-
2019
- 2019-10-18 CN CN202411435476.8A patent/CN120305401A/zh active Pending
- 2019-10-18 EP EP19873989.8A patent/EP3866852A4/en active Pending
- 2019-10-18 WO PCT/US2019/056910 patent/WO2020081920A1/en not_active Ceased
- 2019-10-18 CN CN201980083971.8A patent/CN113271971A/zh active Pending
- 2019-10-18 CA CA3117098A patent/CA3117098A1/en active Pending
- 2019-10-18 AU AU2019361120A patent/AU2019361120A1/en active Pending
- 2019-10-18 US US17/286,011 patent/US20210388073A1/en not_active Abandoned
- 2019-10-18 JP JP2021521144A patent/JP2022512735A/ja not_active Withdrawn
- 2019-10-18 KR KR1020217014607A patent/KR20210081366A/ko active Pending
-
2021
- 2021-04-12 IL IL282251A patent/IL282251A/en unknown
-
2024
- 2024-09-04 US US18/824,691 patent/US20250223344A1/en active Pending
- 2024-09-20 JP JP2024163238A patent/JP2025011102A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025011102A5 (https=) | ||
| US12187690B2 (en) | Benzothiadiazepine compounds and their use as bile acid modulators | |
| Lee et al. | Inflammatory and fibrotic mechanisms in NAFLD—Implications for new treatment strategies | |
| Ghanim et al. | Vanillin augments liver regeneration effectively in Thioacetamide induced liver fibrosis rat model | |
| US11225466B2 (en) | Benzothiadiazepine compounds and their use as bile acid modulators | |
| Tipoe et al. | Epigallocatechin-3-gallate (EGCG) reduces liver inflammation, oxidative stress and fibrosis in carbon tetrachloride (CCl4)-induced liver injury in mice | |
| Friedman | Molecular mechanisms of hepatic fibrosis and principles of therapy | |
| Bruck et al. | Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats | |
| JP7010836B2 (ja) | 胆汁鬱滞性疾患の処置の方法 | |
| US20210179572A1 (en) | Benzothiadiazepine compounds and their use as bile acid modulators | |
| ES2316553T3 (es) | Analogos de lipoxina como nuevos inhibidores de la angiogenesis. | |
| CN110536682A (zh) | 依拉非诺或其衍生物与抗nash、抗纤维化或抗胆汁淤积药剂的组合 | |
| Abe et al. | Simvastatin attenuates intestinal fibrosis independent of the anti-inflammatory effect by promoting fibroblast/myofibroblast apoptosis in the regeneration/healing process from TNBS-induced colitis | |
| Di Pasqua et al. | FXR agonists INT‐787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet‐induced ob/ob mouse model of NASH | |
| Evans et al. | Interactive roles of superoxide and inducible nitric oxide synthase in rat intestinal injury provoked by non-steroidal anti-inflammatory drugs | |
| Schmitt et al. | Complement factor C5 deficiency significantly delays the progression of biliary fibrosis in bile duct-ligated mice | |
| D’Argenio et al. | Garlic extract prevents CCl4-induced liver fibrosis in rats: The role of tissue transglutaminase | |
| Zeng et al. | Resolvin D1 prevents epithelial-to-mesenchymal transition and reduces collagen deposition by stimulating autophagy in intestinal fibrosis | |
| JP2017536380A5 (https=) | ||
| ES3015230T3 (en) | Polypeptide and application thereof | |
| Park et al. | Ellagic acid, a functional food component, ameliorates functionality of reverse cholesterol transport in murine model of atherosclerosis | |
| ZHOU et al. | Renal protective effects of blocking the intrarenal renin-angiotensin system: angiotensin II type I receptor antagonist compared with angiotensin-converting enzyme inhibitor | |
| Mukherjee et al. | Transgenic tomatoes expressing the 6F peptide and ezetimibe prevent diet-induced increases of IFN-β and cholesterol 25-hydroxylase in jejunum | |
| Hu et al. | Resveratrol improved atherosclerosis by increasing LDLR levels via the EGFR-ERK1/2 signaling pathway | |
| Yata et al. | Expression of matrix metalloproteinase-13 and tissue inhibitor of metalloproteinase-1 in acute liver injury |